to give similar results. PGI2, unlike other prostaglandins, is not extensively metabolized by the lung, and experiments using bioassay suggested that production by the lung and perhaps other sources permitted PGI2 to function as a circulating platelet-inhibitory hormone in rabbits and cats.9 '0 Apparent confirmation of this observation in man was soon provided by transpulmonary measurements of 6-keto-PGFia by GC/MS in patients undergoing cardiac catheterization."I The inactive hydration product of PGJ2, 6-keto-PGFI, , is formed nonenzymatically and is more stable than the parent compound. This study'1 suggested that the pulmonary production rate of PGI2 was in the order of 5 ng/kg/min in man, higher than the threshold dose required to inhibit platelet aggregation ex vivo when synthetic PGI2 was infused into human volunteers. '2 Radioimmunoassays for TxB2, the inactive hydration product of TxA2, were developed and applied to measurements in human plasma, and many reports characterized a supposed "imbalance of the PGI2/ TxA2 ratio" in a variety of human diseases. However, in the past 2 years, evidence has appeared that the secretion rate of endogenous PGI2 into the circulation of human volunteers is extremely low (-0.09 ng/kg/ min),'3 that 6-keto-PGF,, in human plasma obtained under resting conditions is in the low picogram range (< 5 pg),'1'8 and that pulmonary release of PGI2 is undetectable in healthy volunteers.'9 Thus, although PGI2 is probably important in local platelet-vascular interactions, it does not function as a circulating hormone under physiologic conditions in man. Similarly, we have found that immunoreactive TxB2 is undetectable in human plasma obtained from healthy volunteers when care was taken to avoid artifacts induced by sampling and technically acceptable assay methods with limits of sensitivity in the low picogram range were combined with highly specific antibodies.
The importance of these observations is that they invalidate the majority of studies pertaining to endogenous biosynthesis of PGI2 and TxA2 in human disease. Studies of PGI2 and TxA2 production in the human coronary circulation illustrate this point. Samples are usually obtained after insertion of catheters, a procedure that is likely to traumatically stimulate vascular PGI2 synthesis. Other aspects of the procedure, such as the use of heparin and radiocontrast media, may also alter synthesis of either compound. Platelet activation at the catheter tip and ex vivo prostanoid formation represent other sources of potential artifact. Finally, it may not be apparent that levels of these compounds are artifactually elevated, because the data are often presented as 6-keto-PGF,JTxB2 ratios or coronary sinus/ aortic blood ratios of either compound.
It has been proposed that substantial quantitative differences between bioassay estimates of prostacyclin-like activity (2-6 ng/ml)20 and measurement of 6-keto-PGFia in plasma by negative ion chemical ioniza-tion GC/MS (0.5-2 pg/ml)'8 may result from predominant conversion of PGI2 to 6-keto-PGE,,20 a biologically active compound21 22 that is a putative metabolite of PGI2 in vivo.23 However, this seems highly unlikely because studies of the metabolic disposition of PGI2 in man have failed to detect metabolites with the 6-keto-PGE structure24 and because infusion of synthetic PGI2 in volunteers does not result in accumulation of 6-keto-PGE, in plasma. 25 One method of circumventing problems of sampling-induced artifact and ex vivo prostaglandin formation is by measurement of metabolites that have an extended half-life. Although the 13,14-dihydro-6,15-diketo-PGF,, metabolite of PGI2 has a longer half-life than 6-keto-PGF1a and has been identified in human plasma after PGI2 infusions,26 experience with other prostaglandins has shown that the metabolites initially formed from the hydration products are rapidly replaced by more polar products as the major compounds in blood. Measurement of tetranor metabolites has been recently27 utilized to detect phasic release of PGF2 in patients with primary dysmenorrhea who suffer episodic pain. Quantitative assays for stable oxidative metabolites of PGI2 and TxA2 in plasma are currently being developed.
An alternative approach has been the measurement of prostaglandin breakdown products in urine. When this is performed by GC/MS, it represents a highly specific, noninvasive index of endogenous prostaglandin biosynthesis. Measurement of urinary metabolites by RIA is even more liable to problems of sensitivity and specificity than in plasma. Performance of RIAs on unextracted urine and the use of antibodies with high cross-reactivity to structurally related compounds have been common sources of error. However, the combination of rigorous sample purification with highly specific antibodies has permitted the measurement of 6-keto-PGF 16, 28 and TxB229 in urine by RIA. Although 6-keto-PGF,24 and TxB230 are urinary metabolites of infused PGI2 and TxB2 in man, these indexes are likely to predominantly reflect renal PGI2 and TxA2 generation under physiologic conditions. 16, 31 Should extrarenal production of either compound be increased (e.g., during a vascular catastrophe), one would anticipate an increase in the urinary levels of the relevant hydration product. For example, urinary 6-keto-PGF1a excretion is increased in preterm infants with persistent ductus arteriosus and respiratory distress syndrome in whom an increase in systemic prostaglandin biosynthesis is likely. 32 The dinor metabolites of 6-ketoPGF1a and TxB2 are the most abundant products of systemically administered, radiolabeled PGI224 and TxB2,30 respectively, in man (table 1) . Thus, urinary levels of 2,3-dinor-6-keto-PGF,a (PGI-M) and 2,3-dinor-TxB2 (Tx-M) have been used to quantify the effects of aspirin and similar drugs upon systemic PGI2 and TxA2 synthesis in man33-35 and to accurately predict plasma levels of endogenous PGI2 in the low picogram range. '3 Although these measurements represent the only noninvasive method of quantifying endogenous generation of PGI2 and TxA2, they are not specific to the tissue or origin of these compounds. More specific indexes have been studied ex vivo, such as TxB2 formation in serum28 36 or in stimulated platelet-rich plasma33 or 6-keto-PGF1a formation by biopsies of vascular 
